A PHASE III TRIAL OF THE USE OF LONG TERM TOTAL ANDROGEN SUPPRESSION FOLLOWING NEOADJUVANT HORMONAL CYTOREDUCTION AND RADIOTHERAPY IN LOCALLY ADVANCED CARCINOMA OF THE PROSTATE.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 02 Sep 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

31 Aug 2022 According to a Veracyte media release, analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 Randomized Phase III Trials will be presented at the ESMO 2022 Congress.
19 Feb 2022 Results assessing prognostic biomarkers in localized prostate cancer using five phase III randomized trials (RTOG 9202, 9408, 9413, 9910, and 0126), by leveraging multi-modal deep learning on digital histopathologypresented at the 2022 Genitourinary Cancers Symposium.
22 Oct 2008 New trial record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com